News
TGTX
33.09
-1.22%
-0.41
TGTX March 28th Options Begin Trading
NASDAQ · 2d ago
Weekly Report: what happened at TGTX last week (0127-0131)?
Weekly Report · 6d ago
Confidence in TG Therapeutics’ Growth: Buy Rating Affirmed Amid Solid Financial Performance
TipRanks · 01/29 12:05
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
NASDAQ · 01/27 17:00
Weekly Report: what happened at TGTX last week (0120-0124)?
Weekly Report · 01/27 11:58
TG Therapeutics: Entering 2025 With Increased Investor Expectations
Seeking Alpha · 01/23 19:48
TG Therapeutics: 2025 Revenues Will Smash Expectations
Seeking Alpha · 01/21 07:17
Weekly Report: what happened at TGTX last week (0113-0117)?
Weekly Report · 01/20 11:46
What Moved Markets This Week
Seeking Alpha · 01/18 11:33
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +
Seeking Alpha · 01/17 19:30
TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade)
Seeking Alpha · 01/16 13:02
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
NASDAQ · 01/15 14:10
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
NASDAQ · 01/15 13:15
TG Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Dow Jones · 01/15 12:06
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts
Benzinga · 01/15 12:00
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
TipRanks · 01/15 11:25
ClearBridge Small Cap Growth Fund Q4 2024 Commentary
Seeking Alpha · 01/15 11:09
TG Therapeutics Reports Strong Revenue and Future Goals
TipRanks · 01/14 21:27
TG THERAPEUTICS INC - SEES FY 2025 GLOBAL REVENUE $540 MILLION
Reuters · 01/14 21:03
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug
Dow Jones · 01/14 20:51
More
Webull provides a variety of real-time TGTX stock news. You can receive the latest news about Tg Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.